Literature DB >> 20012290

Risks and adequacy of an optimized surgical approach to the primary surgical management of papillary thyroid carcinoma treated during 1999-2006.

Clive S Grant1, John M Stulak, Geoffrey B Thompson, Melanie L Richards, Carl C Reading, Ian D Hay.   

Abstract

BACKGROUND: Intense disease surveillance and frequent lymph node metastases (LNMs) in papillary thyroid cancer (PTC) have resulted in increased locoregional recurrences. We examined the safety and efficacy of an optimized surgical approach including preoperative ultrasonography (US), bilateral thyroidectomy, routine compartment VI dissection, and lateral neck dissection for LNM.
METHODS: During 1999-2006, a total of 420 patients underwent optimized primary surgery; 291(69%) females, median age 46 years; follow-up 98%, median 4.4 years. Patients were reviewed for tumor characteristics, pattern of LNM, staging, and outcomes.
RESULTS: Total or near-total thyroidectomy was performed in 212 (51%) and 208 (49%) patients, respectively. Tumors were multicentric, 40% (average 1.7 cm); were bilateral, 30%; and showed extrathyroidal extension, 17%. Overall, 223 (53%) patients had LNMs: 213 (51%) were central and 85 (20%) were lateral jugular. pTNM staging: I, 258 (61%); II, 35 (8%); III, 88 (21%); IV, 39 (9%). AGES (age, grade, extension, and size-thyroid tumor; and MACIS (metastasis, age, completeness of resection, invasion, and size) prognostic scores were low risk in 362 (86%) and 352 (84%), respectively. Relapse developed in 57 (14%) patients: LNM in 44, soft tissue local recurrence (LR) in 5, distant metastases (DM) in 8. Hypoparathyroidism occurred in 5 (1.2%) patients and 1 had unintentional laryngeal nerve damage. Relapse with LNM occurred in previously operated fields in 19 (5%) patients, 11(3%) from disease virulence (LR or DM), preoperative false-negative (FN) US in 12 (3%), and combination of FN-US and recurrence in the operated field in 5 (1%) patients.
CONCLUSIONS: Recurrence was limited to 5% of patients when the extent of disease was accurately defined and potentially curable. This optimized surgical strategy is relatively safe.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20012290     DOI: 10.1007/s00268-009-0307-9

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  28 in total

1.  AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology.

Authors:  R H Cobin; H Gharib; D A Bergman; O H Clark; D S Cooper; G H Daniels; R A Dickey; D S Duick; J R Garber; I D Hay; J S Kukora; H M Lando; A B Schorr; M A Zeiger
Journal:  Endocr Pract       Date:  2001 May-Jun       Impact factor: 3.443

2.  Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study.

Authors:  Catharina Ihre Lundgren; Per Hall; Paul W Dickman; Jan Zedenius
Journal:  Cancer       Date:  2006-02-01       Impact factor: 6.860

3.  Prognosis after lymph node recurrence in papillary thyroid carcinoma depends on age.

Authors:  P E Voutilainen; M M Multanen; A K Leppäniemi; C H Haglund; R K Haapiainen; K O Franssila
Journal:  Thyroid       Date:  2001-10       Impact factor: 6.568

Review 4.  The value of lymph-node dissection in patients with differentiated thyroid cancer.

Authors:  S Noguchi; N Murakami
Journal:  Surg Clin North Am       Date:  1987-04       Impact factor: 2.741

Review 5.  Compartment-mediated dissection for papillary thyroid cancer.

Authors:  J F Moley; S A Wells
Journal:  Langenbecks Arch Surg       Date:  1999-02       Impact factor: 3.445

6.  Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer.

Authors:  Mark Sywak; Lachlan Cornford; Paul Roach; Peter Stalberg; Stan Sidhu; Leigh Delbridge
Journal:  Surgery       Date:  2006-11-01       Impact factor: 3.982

7.  Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer.

Authors:  John M Stulak; Clive S Grant; David R Farley; Geoffrey B Thompson; Jon A van Heerden; Ian D Hay; Carl C Reading; J William Charboneau
Journal:  Arch Surg       Date:  2006-05

8.  Extent of surgery affects survival for papillary thyroid cancer.

Authors:  Karl Y Bilimoria; David J Bentrem; Clifford Y Ko; Andrew K Stewart; David P Winchester; Mark S Talamonti; Cord Sturgeon
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

9.  Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.

Authors:  K C Loh; F S Greenspan; L Gee; T R Miller; P P Yeo
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

10.  Operative technique for modified radical neck dissection in papillary thyroid carcinoma.

Authors:  John R Porterfield; David A Factor; Clive S Grant
Journal:  Arch Surg       Date:  2009-06
View more
  17 in total

1.  A novel definition of extrathyroidal invasion for patients with papillary thyroid carcinoma for predicting prognosis.

Authors:  Muneki Hotomi; Iwao Sugitani; Kazuhisa Toda; Kazuyoshi Kawabata; Yoshihide Fujimoto
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

2.  Pattern of initial metastasis in the cervical lymph node from papillary thyroid carcinoma.

Authors:  Naoyoshi Onoda; Tetsuro Ishikawa; Hidemi Kawajiri; Tsutomu Takashima; Kosei Hirakawa
Journal:  Surg Today       Date:  2012-06-26       Impact factor: 2.549

3.  Managing patients with a preoperative diagnosis of AJCC/UICC stage I (T1N0M0) papillary thyroid carcinoma: East versus West, whose policy is best?

Authors:  Ian D Hay
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

4.  The role of preoperative neck ultrasounds to assess lymph nodes in patients with suspicious or indeterminate thyroid nodules.

Authors:  Rashmi Roy; Guennadi Kouniavsky; Raghunandan Venkat; Erin A Felger; Zita Shiue; Eric Schneider; Martha A Zeiger
Journal:  J Surg Oncol       Date:  2011-10-17       Impact factor: 3.454

5.  Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.

Authors:  Aubrey A Carhill; Danielle R Litofsky; Douglas S Ross; Jacqueline Jonklaas; David S Cooper; James D Brierley; Paul W Ladenson; Kenneth B Ain; Henry G Fein; Bryan R Haugen; James Magner; Monica C Skarulis; David L Steward; Mingxhao Xing; Harry R Maxon; Steven I Sherman
Journal:  J Clin Endocrinol Metab       Date:  2015-07-14       Impact factor: 5.958

6.  Technical hints and potential pitfalls in modified radical neck dissection for thyroid cancer.

Authors:  Antonio Sitges-Serra; Leyre Lorente; Juan J Sancho
Journal:  Gland Surg       Date:  2013-11

7.  American Thyroid Association statement on preoperative imaging for thyroid cancer surgery.

Authors:  Michael W Yeh; Andrew J Bauer; Victor A Bernet; Robert L Ferris; Laurie A Loevner; Susan J Mandel; Lisa A Orloff; Gregory W Randolph; David L Steward
Journal:  Thyroid       Date:  2015-01       Impact factor: 6.568

8.  Papillary Thyroid Carcinoma (PTC) in Children and Adults: Comparison of Initial Presentation and Long-Term Postoperative Outcome in 4432 Patients Consecutively Treated at the Mayo Clinic During Eight Decades (1936-2015).

Authors:  Ian D Hay; Tammi R Johnson; Suneetha Kaggal; Megan S Reinalda; Nicole M Iniguez-Ariza; Clive S Grant; Siobhan T Pittock; Geoffrey B Thompson
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

9.  Variation in the management of thyroid cancer.

Authors:  Megan R Haymart; Mousumi Banerjee; Di Yang; Andrew K Stewart; James C Sisson; Ronald J Koenig; Gerard M Doherty; Jennifer J Griggs
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

10.  Prophylactic lymph node dissection in papillary thyroid carcinoma: is there a place for lateral neck dissection?

Authors:  Romain Ducoudray; Christophe Trésallet; Gaelle Godiris-Petit; Frédérique Tissier; Laurence Leenhardt; Fabrice Menegaux
Journal:  World J Surg       Date:  2013-07       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.